| Date Filed | Type | Description |
| 11/09/2020 |
GN
| LogicBio Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update |
| 11/04/2020 |
GN
| LogicBio Therapeutics Receives FDA Fast Track Designation for LB-001 for the Treatment of Methylmalonic Acidemia (MMA) |
| 11/03/2020 |
GN
| LogicBio Therapeutics Announces Appointment of Veteran Biotech Executive Mariana Nacht, Ph.D., as Chief Scientific Officer and Kyle Chiang, Ph.D., Promoted to Chief Operating Officer |
| 10/05/2020 |
GN
| LogicBio Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares |
| 10/01/2020 |
GN
| LogicBio Therapeutics Announces Pricing of Public Offering of Common Stock |
| 09/25/2020 |
GN
| LogicBio Therapeutics to Present at the Jefferies Virtual Gene Editing/Therapy Summit October 2, 2020 |
| 09/25/2020 |
GN
| LogicBio Therapeutics to Present at the 4th Annual Chardan Virtual Genetic Medicines Conference October 5, 2020 |
| 08/10/2020 |
GN
| LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients |
| 08/10/2020 |
GN
| LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates |
| 06/05/2020 |
GN
| LogicBio Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders |
| 05/28/2020 |
GN
| LogicBio Therapeutics to Present at the Jefferies Virtual Healthcare Conference |
| 05/14/2020 |
GN
| LOGC DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies LogicBio Therapeutics, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: May 18, 2020 |
| 05/11/2020 |
GN
| LogicBio Reports First Quarter 2020 Financial Results and Provides Business Updates |
| 05/07/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC |
| 05/05/2020 |
GN
| ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds LogicBio Therapeutics, Inc. Investors of the Important Deadline in Securities Class Action First Filed by Firm – LOGC |
| 04/28/2020 |
GN
| LOGC & PAYS INVESTOR UPDATE: Bronstein, Gewirtz & Grossman LLC Updates Investors of Class Actions and Encourages Investors to Contact the Firm |
| 04/27/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC |
| 04/25/2020 |
GN
| ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds LogicBio Therapeutics, Inc. Investors of the Important Deadline in Securities Class Action First Filed by Firm – LOGC |
| 04/23/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC |
| 04/15/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC |
| 04/09/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC |
| 04/07/2020 |
GN
| LOGC DEADLINE NOTICE, ROSEN, A TOP LAW FIRM, Reminds LogicBio Therapeutics, Inc. Investors of Important Deadline in Securities Class Action Commenced by Firm; Investors with Large Losses Should Contact Firm – LOGC |
| 04/01/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LogicBio Therapeutics, Inc. – LOGC |
| 04/01/2020 |
GN
| Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Alpha and Omega Semiconductor, LogicBio, PaySign, and XP and Encourages Investors to Contact the Firm |
| 03/26/2020 |
GN
| LOGC INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies LogicBio Therapeutics, Inc. Investors of Class Action and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm |
| 03/25/2020 |
GN
| Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cronos Group, Gulfport Energy, Alpha and Omega Semiconductor, and LogicBio Therapeutics and Encourages Investors to Contact the Firm |
| 03/19/2020 |
GN
| Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against LogicBio Therapeutics, Inc. (LOGC) |
| 03/19/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC |
| 03/16/2020 |
GN
| LogicBio Therapeutics Appoints Mark Enyedy to its Board of Directors |
| 03/02/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC |
| 02/27/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC |
| 02/19/2020 |
GN
| ROSEN, NATIONAL TRIAL LAWYERS, Continues to Investigate Securities Claims Against LogicBio Therapeutics, Inc. – LOGC |
| 01/10/2020 |
GN
| LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones |
| 12/17/2019 |
GN
| LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of Pharmaceutically-Driven Selective Advantage for Future GeneRide™ Candidates |
|